Daewoong Co Ltd is a Korea-based holding company engaged in the manufacture and sale of pharmaceuticals. The Company operates its business mainly through subsidiaries including Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd, Daewoong Development Co Ltd, and Hanall Biopharma Co Ltd. Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd and Hanall Biopharma Co Ltd are engaged in the manufacture and sale of pharmaceuticals. Daewoong Development Co Ltd is engaged in real estate rental and supply business. In addition, IDS&Trust Co Ltd manufactures and sells communication-related devices. Daewoong Life Science Co Ltd is engaged in food processing and sales. Pampaeg Co Ltd is engaged in the packaging business of quasi-drugs. Daewoong Management Development Institute Co Ltd is engaged in management and industrial training projects.

Employees

353

Sector

Pharmaceuticals

Calendar

2025-03-24 - Q4 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
24-10-11	27,400.00 ₩	+1.67%	205,016
24-10-10	26,950.00 ₩	+10.45%	281,828
24-10-08	24,400.00 ₩	+8.93%	257,018
24-10-07	22,400.00 ₩	+0.45%	48,296
24-10-04	22,300.00 ₩	-0.45%	88,481

End-of-day quote Korea S.E., October 10, 2024

More quotes

Income Statement and Estimates

income-statement-evolution-chart DAEWOONG-CO-LTD

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Korea S.E. Other stock markets 2024-10-11			5-day change	1st Jan Change
27,400.00 ^KRW	+1.67%		+22.87%	+32.69%

Aug. 14	Daewoong Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
May. 14	Daewoong Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Capitalization	1,120B 831M	P/E ratio 2022	8.25x	P/E ratio 2023	5.59x
Enterprise value	1,302B 966M	EV / Sales 2022	0.53x	EV / Sales 2023	0.57x
Free-Float	31.93%	Yield 2022	0.49%	Yield 2023	0.48%

Daewoong Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Aug. 14	CI
Daewoong Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Korean Sugar Imports Plunge 14% as Diabetes Cases Surge	Apr. 24	MT
Daewoong Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 08	CI
Daewoong Pharmaceutical Secures Approval for Stem Cell Processing Facility in Indonesia	Feb. 15	MT
Tranche Update on Daewoong Co., Ltd.'s Equity Buyback Plan announced on July 27, 2023.	Feb. 05	CI
Tranche Update on Daewoong Co., Ltd.'s Equity Buyback Plan announced on July 27, 2023.	Jan. 31	CI
Daewoong Co., Ltd.'s Equity Buyback announced on July 27, 2023, has closed with 690,630 shares, representing 1.66% for KRW 9,997.24 million.	Jan. 30	CI
Zydus Unit, Daewoong Pharma to Co-Develop, Commercialize Leuprolide Acetate in US	Dec. 11	MT
Daewoong Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Tranche Update on Daewoong Co., Ltd.'s Equity Buyback Plan announced on July 27, 2023.	Nov. 03	CI
Hyphens Pharma Unit to Distribute Daewoong Pharmaceutical's Nabota Botox in Malaysia	23-08-30	MT
Daewoong Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI

MÄRKTE ASIEN/Powell-Aussagen ermutigen Anleger - Sydney fällt zurück	21-06-23
MÄRKTE ASIEN/Erholt - Steigende Corona-Zahlen belasten in Taiwan	21-05-04
BHP : MÄRKTE ASIEN/Schanghai schwach - Kupferpreis sehr fest	21-02-22
Samsung Electronics : MÄRKTE ASIEN/Japan führt Börsen an - Kupferpreis sehr fest	21-02-22
MÄRKTE ASIEN/Fest - Softbank auf Rekordhoch - Imax-Hausse in Hongkong	21-02-16

Daewoong Co., Ltd. Stock

Equities

A003090

KR7003090008

Pharmaceuticals

Valuation: Daewoong Co., Ltd.

Chart: Daewoong Co., Ltd.

Latest news: Daewoong Co., Ltd.

News in other languages: Daewoong Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Daewoong Co., Ltd.

ETFs: Daewoong Co., Ltd.

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 day	+1.67%
1 week	+22.87%
Current month	+16.60%
1 month	+14.41%
3 months	+33.01%
6 months	+47.07%
Current year	+32.69%

Director	Title	Age	Since
Jae-Chun Yoon CEO	Chief Executive Officer	65	85-07-31
Ki-Ho Song DFI	Director of Finance/CFO	53	-
Woo-Bang Jeon AUD	Comptroller/Controller/Auditor	63	19-12-31

Name	Weight	AuM	1st Jan change	Investor Rating
SIMPLIFY EMERGING MARKETS PLUS DOWNSIDE CONVEXITY ETF - USD	0.00%	4 M€	-4.41%	-
LEADERSHARES EQUITY SKEW ETF - USD	0.00%	127 M€	+9.50%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
DAEWOONG CO., LTD.	+1.67%	+22.87%	+55.68%	-14.24%	830M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+0.75%	-0.42%	+68.50%	+128.45%	54.26B
OTSUKA HOLDINGS CO., LTD.	-0.12%	+3.45%	+68.62%	+82.17%	31.95B
SANDOZ GROUP AG	-0.11%	+6.80%	+47.01%	-	18.99B
CIPLA LIMITED	-1.43%	-1.70%	+36.16%	+74.64%	15.32B
ZYDUS LIFESCIENCES LIMITED	+0.70%	+0.67%	+77.44%	+94.07%	12.73B
THE MEDICINES COMPANY	-.--%	+0.14%	-	-	6.79B
ONO PHARMACEUTICAL CO., LTD.	-1.85%	-0.85%	-28.40%	-18.54%	6.27B
GLENMARK PHARMACEUTICALS LIMITED	+1.69%	+7.70%	+129.36%	+235.33%	6.01B
STADA ARZNEIMITTEL	-.--%	-1.95%	-	-	5.73B
Average	+0.13%	+3.67%	+56.80%	+83.13%	15.89B
Weighted average by Cap.	+0.14%	+1.57%	+61.40%	+103.80%

	2022	2023
Net sales	1,697B 1.26B	1,814B 1.35B
Net income	103B 76.1M	153B 113M
Net Debt	58.39B 43.33M	182B 135M

Manager	Title	Age	Since
Jae-Chun Yoon CEO	Chief Executive Officer	65	85-07-31
Hoon-Seok Lee BRD	Director/Board Member	59	22-03-28
Young-Cheol Kang BRD	Director/Board Member	68	22-03-28